C07K 2317/524
Ch2 domain
Official title: CH2 domain
C07K2317/524 (Ch2 domain) appears on 962 US grants and 2,220 published applications in this corpus.
Search patents in C07K- Granted patents
- 962
- Published applications
- 2,220
- Assignees
- 653
- Inventors
- 4,044
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 1 | 5 |
| 2005 | 0 | 3 |
| 2006 | 1 | 4 |
| 2007 | 0 | 8 |
| 2008 | 3 | 4 |
| 2009 | 2 | 12 |
| 2010 | 1 | 13 |
| 2011 | 5 | 16 |
| 2012 | 7 | 27 |
| 2013 | 11 | 40 |
| 2014 | 21 | 45 |
| 2015 | 27 | 65 |
| 2016 | 33 | 105 |
| 2017 | 49 | 103 |
| 2018 | 48 | 125 |
| 2019 | 68 | 128 |
| 2020 | 91 | 159 |
| 2021 | 87 | 219 |
| 2022 | 97 | 207 |
| 2023 | 99 | 221 |
| 2024 | 101 | 272 |
| 2025 | 135 | 259 |
| 2026 | 75 | 179 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Methods and antibody compositions for tumor treatment29 Sep 2026US 12,747,300 B2Regeneron Pharmaceuticals, Inc.
- Immunoglobulin variants15 Sep 2026US 12,735,502 B2Novartis AG
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Cd3 binding molecules8 Oct 2026US 2026/0308254 A1Merus N.V.
- Agents that bind to cd16a and uses thereof8 Oct 2026US 2026/0308258 A1Avantgen, Inc.
- Il12rb2 binding molecules and methods of use8 Oct 2026US 2026/0308265 A1Synthekine, Inc.
- Engineered Antibodies and Uses Thereof8 Oct 2026US 2026/0308277 A1Invitrogen Bioservices India Private Limited
- Methods of producing multimeric proteins in eukaryotic host cells1 Oct 2026US 2026/0297125 A1Genentech, Inc.
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Polypeptide variants with altered effector function373US 7,332,581 B2Genentech, Inc. · 2008
- Fc variants with altered binding to FcRn193US 8,367,805 B2Xencor, Inc. · 2013
- Antibodies with modified isoelectric points139US 8,637,641 B2Xencor, Inc. · 2014
- Methods and compositions for inhibiting CD32B expressing cells121US 8,063,187 B2Xencor, Inc. · 2011